We have recognized revenue from our collaboration and license agreements as follows (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2013			2012			2013			2012
Novartis:
Recognition of upfront license fee	$	—	$		738	$		—	$		53,846
Reimbursement of research and development expense		—			—			—			16,238
Novartis total		—			738			—			70,084

BMS and Pfizer:
Recognition of research and development services		772			—			3,865			—
BMS and Pfizer total		772			—			3,865			—

Bayer and Janssen:
Recognition of research and development services		1,028			—			3,466			—
Bayer and Janssen total		1,028			—			3,466			—

Lee’s:
Recognition of research and development services		78			—			130			—
Lee’s total		78			—			130			—

Daiichi Sankyo:
Recognition of research and development services		888			—			1,013			—
Daiichi Sankyo total		888			—			1,013			—

Total collaboration and license revenue	$	2,766	$		738	$		8,474	$		70,084